Advances in Medical Imaging for the Diagnosis and Management of Common Genitourinary Cancers

Overview

Journal Urol Oncol

Publisher Elsevier

Date 2017 May 17

PMID 28506596

Citations 22

Authors

Mohammad H Bagheri

Mark A Ahlman

Liza Lindenberg

Baris Turkbey

Jeffrey Lin

Ali Cahid Civelek

Ashkan A Malayeri

Piyush K Agarwal

Peter L Choyke

Les R Folio

Andrea B Apolo

Affiliations

Soon will be listed here.

Abstract

Medical imaging of the 3 most common genitourinary (GU) cancers-prostate adenocarcinoma, renal cell carcinoma, and urothelial carcinoma of the bladder-has evolved significantly during the last decades. The most commonly used imaging modalities for the diagnosis, staging, and follow-up of GU cancers are computed tomography, magnetic resonance imaging (MRI), and positron emission tomography (PET). Multiplanar multidetector computed tomography and multiparametric MRI with diffusion-weighted imaging are the main imaging modalities for renal cell carcinoma and urothelial carcinoma, and although multiparametric MRI is rapidly becoming the main imaging tool in the evaluation of prostate adenocarcinoma, biopsy is still required for diagnosis. Functional and molecular imaging using 18-fluorodeoxyglucose-PET and sodium fluoride-PET are essential for the diagnosis, and especially follow-up, of metastatic GU tumors. This review provides an overview of the latest advances in the imaging of these 3 major GU cancers.

Citing Articles

Harnessing Artificial Intelligence for the Detection and Management of Colorectal Cancer Treatment.

Jacob M, Reddy R, Garcia R, Reddy A, Khemka S, Roghani A Cancer Prev Res (Phila). 2024; 17(11):499-515.

PMID: 39077801 PMC: 11534518. DOI: 10.1158/1940-6207.CAPR-24-0178.

Neighborhood social vulnerability and disparities in time to kidney cancer surgical treatment and survival in Arizona.

Valencia C, Wightman P, Morrill K, Hsu C, Arif-Tiwari H, Kauffman E Cancer Med. 2024; 13(3):e7007.

PMID: 38400688 PMC: 10891465. DOI: 10.1002/cam4.7007.

Contemporary Clinical Definitions, Differential Diagnosis, and Novel Predictive Tools for Renal Cell Carcinoma.

Novacescu D, Feciche B, Cumpanas A, Bardan R, Rusmir A, Bitar Y Biomedicines. 2022; 10(11).

PMID: 36428491 PMC: 9687297. DOI: 10.3390/biomedicines10112926.

Role of 18F-FDG PET/CT for detection of recurrence and metastases in renal cell carcinoma-are we underusing PET/CT?.

Pereira M, Punatar C, Singh N, Sagade S Diagn Interv Radiol. 2022; 28(5):498-502.

PMID: 36218153 PMC: 9682604. DOI: 10.5152/dir.2022.21096.

Role of ultra-high b-value DWI in the imaging of hereditary leiomyomatosis and renal cell carcinoma (HLRCC).

Chaurasia A, Gopal N, Dehghani Firouzabadi F, Yazdian Anari P, Wakim P, Ball M Abdom Radiol (NY). 2022; 48(1):340-349.

PMID: 36207629 PMC: 10681094. DOI: 10.1007/s00261-022-03689-w.

References

Ciancio G, Soloway M . Resection of the abdominal inferior vena cava for complicated renal cell carcinoma with tumour thrombus. BJU Int. 2005; 96(6):815-8. DOI: 10.1111/j.1464-410X.2005.05719.x. View

Hugen C, Duddalwar V, Daneshmand S . Preoperative Imaging for Clinical Staging Prior to Radical Cystectomy. Curr Urol Rep. 2016; 17(9):62. PMC: 7474952. DOI: 10.1007/s11934-016-0618-y. View

Rosenkrantz A, Ginocchio L, Cornfeld D, Froemming A, Gupta R, Turkbey B . Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A Multicenter Study of Six Experienced Prostate Radiologists. Radiology. 2016; 280(3):793-804. PMC: 5006735. DOI: 10.1148/radiol.2016152542. View

Greer M, Brown A, Shih J, Summers R, Marko J, Law Y . Accuracy and agreement of PIRADSv2 for prostate cancer mpMRI: A multireader study. J Magn Reson Imaging. 2016; 45(2):579-585. PMC: 7900895. DOI: 10.1002/jmri.25372. View

Giannatempo P, Alessi A, Miceli R, Raggi D, Fare E, Nicolai N . Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma. Clin Genitourin Cancer. 2014; 12(6):433-9. DOI: 10.1016/j.clgc.2014.03.007. View

Choyke P, Walther M, Wagner J, Rayford W, Lyne J, Linehan W . Renal cancer: preoperative evaluation with dual-phase three-dimensional MR angiography. Radiology. 1997; 205(3):767-71. DOI: 10.1148/radiology.205.3.9393533. View

Mena E, Turkbey B, Mani H, Adler S, Valera V, Bernardo M . 11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med. 2012; 53(4):538-45. PMC: 3526004. DOI: 10.2967/jnumed.111.096032. View

Folio L, Turkbey E, Steinberg S, Apolo A . Viable tumor volume: Volume of interest within segmented metastatic lesions, a pilot study of proposed computed tomography response criteria for urothelial cancer. Eur J Radiol. 2015; 84(9):1708-14. PMC: 4545379. DOI: 10.1016/j.ejrad.2015.05.026. View

Lu Y, Chen J, Liang J, Wang H, Lin C, Lin W . Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol. 2011; 81(9):2411-6. DOI: 10.1016/j.ejrad.2011.07.018. View

10.

Ergen F, Hussain H, Caoili E, Korobkin M, Carlos R, Weadock W . MRI for preoperative staging of renal cell carcinoma using the 1997 TNM classification: comparison with surgical and pathologic staging. AJR Am J Roentgenol. 2003; 182(1):217-25. DOI: 10.2214/ajr.182.1.1820217. View

11.

Apolo A, Lindenberg L, Shih J, Mena E, Kim J, Park J . Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer. J Nucl Med. 2016; 57(6):886-92. PMC: 6599519. DOI: 10.2967/jnumed.115.166512. View

12.

Reed Dunnick N . Renal cell carcinoma: staging and surveillance. Abdom Radiol (NY). 2016; 41(6):1079-85. DOI: 10.1007/s00261-016-0692-0. View

13.

Kobayashi K, Bhargava P, Raja S, Nasseri F, Al-Balas H, Smith D . Image-guided biopsy: what the interventional radiologist needs to know about PET/CT. Radiographics. 2012; 32(5):1483-501. DOI: 10.1148/rg.325115159. View

14.

Jambor I, Kuisma A, Ramadan S, Huovinen R, Sandell M, Kajander S . Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Acta Oncol. 2015; 55(1):59-67. DOI: 10.3109/0284186X.2015.1027411. View

15.

Chang C, Shiau Y, Shen Y, Kao A, Lin C, Lee C . Differentiating solitary pulmonary metastases in patients with renal cell carcinomas by 18F-fluoro-2-deoxyglucose positron emission tomography--a preliminary report. Urol Int. 2003; 71(3):306-9. DOI: 10.1159/000072683. View

16.

Mohsen B, Giorgio T, Rasoul Z, Werner L, Ali G, Vahid Reza D . Application of C-11-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature. BJU Int. 2013; 112(8):1062-72. DOI: 10.1111/bju.12279. View

17.

Szabo Z, Mena E, Rowe S, Plyku D, Nidal R, Eisenberger M . Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol. 2015; 17(4):565-74. PMC: 4531836. DOI: 10.1007/s11307-015-0850-8. View

18.

De Cecco C, Darnell A, Rengo M, Muscogiuri G, Bellini D, Ayuso C . Dual-energy CT: oncologic applications. AJR Am J Roentgenol. 2012; 199(5 Suppl):S98-S105. DOI: 10.2214/AJR.12.9207. View

19.

Podoloff D, Ball D, Ben-Josef E, Benson 3rd A, Cohen S, Coleman R . NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw. 2009; 7 Suppl 2:S1-26. DOI: 10.6004/jnccn.2009.0075. View

20.

Yu E, Duan F, Muzi M, Deng X, Chin B, Alumkal J . Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687. J Nucl Med. 2015; 56(3):354-60. PMC: 4410847. DOI: 10.2967/jnumed.114.146936. View